

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 27 (Cancelled).

28 (Withdrawn). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):


formula (3)




wherein R^5 represents R^{51} , R^{52} , R^{53} , R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{70} , R^{71} , R^{72} , R^{73} , R^{74} , R^{75} , R^{76} , R^{77} , or R^{78} ; and R^6 represents hydrogen, R^{62} , R^{63} , R^{64} , or R^{65} :

In re of: 10/553,695


R⁵¹ :




R⁵² :




R⁵³ :




R⁵⁴ :




R⁵⁵ :




R⁵⁶ :




R⁵⁷ :




R⁵⁸ :




R⁵⁹ :




R⁷⁰ :




R⁷¹ :




R⁷² :




R⁷³ :




R⁷⁴ :




R⁷⁵ :




R⁷⁶ :




R⁷⁷ :




R⁷⁸ :




R⁶² :




R⁶⁴ :



R⁶³ :




R⁶⁵ :



29 (Cancelled).


30 (Currently Amended). A method of activating NKT ~~cell~~ cells which comprises administering ~~the cell activator~~ according to ~~claim 28~~ to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein R⁵ represents R⁵¹, R⁵² or R⁵³; and R⁶ represents hydrogen, R⁶², R⁶³, R⁶⁴, or R⁶⁵:


R⁵¹ :




R⁵² :




R⁵³ :






31 (Cancelled).

32 (Currently Amended). A method of accelerating IL-4 production which comprises administering ~~the cell activator according to claim 28~~ to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):
formula (3)




wherein R^5 represents R^{51} , R^{52} or R^{53} ; and R^6 represents hydrogen, R^{62} , R^{63} , R^{64} , or R^{65} :


R^{51} :




R^{52} :




R^{53} :






33 (Cancelled).

34 (Currently Amended). A method of accelerating IFN- γ production which comprises administering ~~the cell activator according to claim 28~~ to a mammal a cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):
formula (3)




wherein R^5 represents R^{51} , R^{52} or R^{53} ; and R^6 represents hydrogen, R^{62} , R^{63} , R^{64} , or R^{65} :


R^{51} :




R^{52} :



R^{53} :





35 (Cancelled).

36 (Currently Amended). A method of activating dendritic ~~cell~~ cells which comprises administering the cell activator to claim 28 to a mammal.

37 (Cancelled).

38 (Previously Presented). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (Cancelled).

40 (Previously Presented). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.

41 (Cancelled).

42 (Currently Amended). A method of activating NK ~~cell~~-cells which comprises administering the cell activator according to claim 28 to a mammal.

43 (Cancelled).

44 (Withdrawn). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (Cancelled).

46 (Withdrawn). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (Cancelled).

48 (Withdrawn). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (Cancelled).

50 (Current Amended). A method of inhibiting ~~viral~~ herpesvirus activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (Cancelled).

52 (Previously Presented). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (Cancelled).

54 (Current Amended). A method of accelerating ~~NO~~
nitrogen monoxide production which comprises administering the
cell activator according to claim 28 to a mammal.

55 (Current Amended). A method of inhibiting ~~viral~~
herpesvirus activity of which comprises administering the cell
activator according to claim 28 to a mammal, wherein R⁶
represents hydrogen.

56 (Current Amended). A method of inhibiting ~~viral~~
herpesvirus activity which comprises administering the cell
activator according to claim 28 to a mammal, wherein R⁵
represents R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵, and R⁵⁶.

57 (New). A method in accordance with claim 50
wherein said herpesvirus is cytomegalovirus.

58 (New). A method in accordance with claim 55
wherein said herpesvirus is cytomegalovirus.

59 (New). A method in accordance with claim 56
wherein said herpesvirus is cytomegalovirus.